Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Abstract Background Atypical tumor response patterns during immune checkpoint inhibitor therapy pose a challenge to clinicians and investigators in immuno-oncology practice. This study evaluated tumor burden dynamics to identify imaging biomarkers for treatment response and overall survival (OS) in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peiyi Xie, Hong Zheng, Haiyang Chen, Kaikai Wei, Ximin Pan, Qinmei Xu, Yongchen Wang, Changguan Tang, Olivier Gevaert, Xiaochun Meng
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	PD-1/PD-L1 inhibitor Immunotherapy Advanced gastrointestinal malignancies Tumor response Pseudoprogression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d5846f0297f24aa9ad1627f2fb45c329
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5846f0297f24aa9ad1627f2fb45c329
record_format	dspace
spelling	oai:doaj.org-article:d5846f0297f24aa9ad1627f2fb45c3292021-11-21T12:30:19ZTumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival10.1186/s12885-021-08944-91471-2407https://doaj.org/article/d5846f0297f24aa9ad1627f2fb45c3292021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08944-9https://doaj.org/toc/1471-2407Abstract Background Atypical tumor response patterns during immune checkpoint inhibitor therapy pose a challenge to clinicians and investigators in immuno-oncology practice. This study evaluated tumor burden dynamics to identify imaging biomarkers for treatment response and overall survival (OS) in advanced gastrointestinal malignancies treated with PD-1/PD-L1 inhibitors. Methods This retrospective study enrolled a total of 198 target lesions in 75 patients with advanced gastrointestinal malignancies treated with PD-1/PD-L1 inhibitors between January 2017 and March 2021. Tumor diameter changes as defined by immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) were studied to determine treatment response and association with OS. Results Based on the best overall response, the tumor diameter ranged from − 100 to + 135.3% (median: − 9.6%). The overall response rate was 32.0% (24/75), and the rate of durable disease control for at least 6 months was 30.7% (23/75, one (iCR, immune complete response) or 20 iPR (immune partial response), or 2iSD (immune stable disease). Using univariate analysis, patients with a tumor diameter maintaining a < 20% increase (48/75, 64.0%) from baseline had longer OS than those with ≥20% increase (27/75, 36.0%) and, a reduced risk of death (median OS: 80 months vs. 48 months, HR = 0.22, P = 0.034). The differences in age (HR = 1.09, P = 0.01), combined surgery (HR = 0.15, P = 0.01) and cancer type (HR = 0.23, P = 0.001) were significant. In multivariable analysis, patients with a tumor diameter with a < 20% increase had notably reduced hazards of death (HR = 0.15, P = 0.01) after adjusting for age, combined surgery, KRAS status, cancer type, mismatch repair (MMR) status, treatment course and cancer differentiation. Two patients (2.7%) showed pseudoprogression. Conclusions Tumor diameter with a < 20% increase from baseline during therapy in gastrointestinal malignancies was associated with therapeutic benefit and longer OS and may serve as a practical imaging marker for treatment response, clinical outcome and treatment decision making.Peiyi XieHong ZhengHaiyang ChenKaikai WeiXimin PanQinmei XuYongchen WangChangguan TangOlivier GevaertXiaochun MengBMCarticlePD-1/PD-L1 inhibitorImmunotherapyAdvanced gastrointestinal malignanciesTumor responsePseudoprogressionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PD-1/PD-L1 inhibitor Immunotherapy Advanced gastrointestinal malignancies Tumor response Pseudoprogression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	PD-1/PD-L1 inhibitor Immunotherapy Advanced gastrointestinal malignancies Tumor response Pseudoprogression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Peiyi Xie Hong Zheng Haiyang Chen Kaikai Wei Ximin Pan Qinmei Xu Yongchen Wang Changguan Tang Olivier Gevaert Xiaochun Meng Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
description	Abstract Background Atypical tumor response patterns during immune checkpoint inhibitor therapy pose a challenge to clinicians and investigators in immuno-oncology practice. This study evaluated tumor burden dynamics to identify imaging biomarkers for treatment response and overall survival (OS) in advanced gastrointestinal malignancies treated with PD-1/PD-L1 inhibitors. Methods This retrospective study enrolled a total of 198 target lesions in 75 patients with advanced gastrointestinal malignancies treated with PD-1/PD-L1 inhibitors between January 2017 and March 2021. Tumor diameter changes as defined by immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) were studied to determine treatment response and association with OS. Results Based on the best overall response, the tumor diameter ranged from − 100 to + 135.3% (median: − 9.6%). The overall response rate was 32.0% (24/75), and the rate of durable disease control for at least 6 months was 30.7% (23/75, one (iCR, immune complete response) or 20 iPR (immune partial response), or 2iSD (immune stable disease). Using univariate analysis, patients with a tumor diameter maintaining a < 20% increase (48/75, 64.0%) from baseline had longer OS than those with ≥20% increase (27/75, 36.0%) and, a reduced risk of death (median OS: 80 months vs. 48 months, HR = 0.22, P = 0.034). The differences in age (HR = 1.09, P = 0.01), combined surgery (HR = 0.15, P = 0.01) and cancer type (HR = 0.23, P = 0.001) were significant. In multivariable analysis, patients with a tumor diameter with a < 20% increase had notably reduced hazards of death (HR = 0.15, P = 0.01) after adjusting for age, combined surgery, KRAS status, cancer type, mismatch repair (MMR) status, treatment course and cancer differentiation. Two patients (2.7%) showed pseudoprogression. Conclusions Tumor diameter with a < 20% increase from baseline during therapy in gastrointestinal malignancies was associated with therapeutic benefit and longer OS and may serve as a practical imaging marker for treatment response, clinical outcome and treatment decision making.
format	article
author	Peiyi Xie Hong Zheng Haiyang Chen Kaikai Wei Ximin Pan Qinmei Xu Yongchen Wang Changguan Tang Olivier Gevaert Xiaochun Meng
author_facet	Peiyi Xie Hong Zheng Haiyang Chen Kaikai Wei Ximin Pan Qinmei Xu Yongchen Wang Changguan Tang Olivier Gevaert Xiaochun Meng
author_sort	Peiyi Xie
title	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
title_short	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
title_full	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
title_fullStr	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
title_full_unstemmed	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
title_sort	tumor response as defined by irecist in gastrointestinal malignancies treated with pd-1 and pd-l1 inhibitors and correlation with survival
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d5846f0297f24aa9ad1627f2fb45c329
work_keys_str_mv	AT peiyixie tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT hongzheng tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT haiyangchen tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT kaikaiwei tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT ximinpan tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT qinmeixu tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT yongchenwang tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT changguantang tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT oliviergevaert tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival AT xiaochunmeng tumorresponseasdefinedbyirecistingastrointestinalmalignanciestreatedwithpd1andpdl1inhibitorsandcorrelationwithsurvival
_version_	1718418973246095360

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Ejemplares similares